Across TCGA pan-cancer cohorts, MIR4435-2HG Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated MIR4435-2HG data layer compared with 22 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher MIR4435-2HG Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MIR4435-2HG expression acts as an unfavorable survival marker.
UCEC are the cancer types where MIR4435-2HG Mutation most reproducibly stratifies survival.